Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TD 139 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Galecto Biotech
  • Most Recent Events

    • 24 May 2017 Results (n=24) of part II, presented at the 113th International Conference of the American Thoracic Society
    • 10 Mar 2017 Results published in a Galecto Biotech media release.
    • 10 Mar 2017 Detailed results from this trial will be presented at the meeting of the American Thoracic Society, according to a Galecto Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top